Insmed Inc’s recent filing unveils that its Chief Operating Officer Adsett Roger unloaded Company’s shares for reported $0.15 million on Jan 12 ’24. In the deal valued at $28.63 per share,5,251 shares were sold. As a result of this transaction, Adsett Roger now holds 148,559 shares worth roughly $4.05 million.
Then, Flammer Martina M.D. sold 4,667 shares, generating $133,616 in total proceeds. Upon selling the shares at $28.63, the Chief Medical Officer now owns 106,898 shares.
Before that, Adsett Roger sold 3,536 shares. Insmed Inc shares valued at $102,190 were divested by the Chief Operating Officer at a price of $28.90 per share. As a result of the transaction, Adsett Roger now holds 153,810 shares, worth roughly $4.19 million.
Wolfe Research initiated its Insmed Inc [INSM] rating to an Outperform in a research note published on February 15, 2024; the price target was $42. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early December with a ‘”an Overweight”‘ rating. Guggenheim started covering the stock on July 26, 2023. It rated INSM as “a Buy”.
Price Performance Review of INSM
On Friday, Insmed Inc [NASDAQ:INSM] saw its stock fall -4.59% to $27.25. Over the last five days, the stock has lost -1.48%. Insmed Inc shares have fallen nearly -12.07% since the year began. Nevertheless, the stocks have risen 63.96% over the past one year. While a 52-week high of $32.00 was reached on 01/02/24, a 52-week low of $16.46 was recorded on 02/22/24. SMA at 50 days reached $27.67, while 200 days put it at $25.60. A total of 2.64 million shares were traded, compared to the trading of 1.0 million shares in the previous session.
Levels Of Support And Resistance For INSM Stock
The 24-hour chart illustrates a support level at 26.65, which if violated will result in even more drops to 26.04. On the upside, there is a resistance level at 28.16. A further resistance level may holdings at 29.06. The Relative Strength Index (RSI) on the 14-day chart is 48.18, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.61, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 50.35%. Stochastics %K at 81.19% indicates the stock is a selling.
The most recent change occurred on December 09, 2022 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating along with a $28 price target.
